Daiichi Sankyo Europe GmbH

http://www.daiichi-sankyo.de

31.08.2020 – 09:00
New 12-month analysis data from ETNA-AF non-interventional study show low bleeding and ICH rates in frail and elderly AF patients on LIXIANA (edoxaban) during routine clinical care
Munich (ots/PRNewswire) - - Newly presented data provide reassurance around edoxaban use in vulnerable populations of frail, elderly and renally impaired patients - Clinician's perception of frailty found to potentially be a better marker of clinical outcomes than age - The global ETNA-AF programme, which includes ...
plus
20.08.2020 – 09:00
ETNA-AF-Europe Registry Data on LIXIANA®(edoxaban) Published in a Leading Cardiology Journal Highlights Important Clinical Considerations for Treating Ageing Patients with Atrial Fibrillation
Munich (ots/PRNewswire) - - Publication highlights Europe-specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients[1] - Findings are ...
plus
14.07.2020 – 14:17
Rates of Bleeding and Venous Thromboembolism (VTE) Events Reported After 12 Months of Edoxaban Treatment Considered Low by Real-world ETNA-VTE Study Investigators
Munich (ots/PRNewswire) - - Daiichi Sankyo presented five abstracts from the Global and European ETNA-VTE registry studies at ISTH 2020 Virtual Congress - Data are from 4,595 VTE patients (mean age 64) from 583 sites across Europe, Japan and other East and South-east Asian countries - Real-world study adds to the ...
plus
18.12.2019 – 09:00
Large Real-World Data Confirm Safety and Effectiveness of LIXIANA® (edoxaban) in Routine Clinical Practice for Elderly AF Patients with Comorbidities
Munich (ots/PRNewswire) - · Results published in the European Heart Journal - Cardiovascular Pharmacotherapy (https://academic.oup.com/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz070/5644339?redirectedFrom=fulltext), showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 ...
plus
04.09.2019 – 08:01
Daiichi Sankyo Presents Positive Results of the ENTRUST-AF PCI Study of LIXIANA® (edoxaban) in Patients with Atrial Fibrillation
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - Data contributes to growing body of ...
plus
02.09.2019 – 14:00
ETNA-AF Registry Data Provide Real-world Evidence of the Efficacy and Safety Profile of LIXIANA® (edoxaban) in Elderly NVAF Patients
- Global and European real-world outcome analyses in non-selected atrial fibrillation (AF) patients on edoxaban, including those who are elderly with comorbidities, were reported at ESC Congress 2019 - At present, the Global ETNA-AF programme is the largest and most comprehensive repository of routine clinical ...
plus
19.03.2019 – 10:30
Data from the Non-interventional EMIT-AF/VTE Study Shows Low Thromboembolic and Bleeding Event Rates in Unselected Elderly AF/VTE Patients on Oral, Once-daily LIXIANA® Undergoing Diagnostic or Therapeutic Procedures
Munich (ots/PRNewswire) - - In 2019, the Edoxaban Clinical Research Programme will deliver new evidence on LIXIANA® (edoxaban) use in clinical practice. EMIT-AF/VTE is one of the first sets of data to be presented - EMIT-AF/VTE is a large observational, multicentre, multinational study on edoxaban peri-procedural ...
plus
19.03.2019 – 09:59
CLEAR Wisdom Demonstrated First-in-class, Oral, Once-daily, ACL Inhibitor Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP
- Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 CLEAR Wisdom at the American College of Cardiology (ACC) 2019 Scientific Sessions - Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated and Adverse Event Profile was Similar to that of Placebo[1] - Bempedoic Acid is an ...
plus
18.03.2019 – 15:01
Daiichi Sankyo Presents Positive Results of the First Randomised, Controlled Trial of Uninterrupted Oral, Once-daily LIXIANA® (edoxaban) in Atrial Fibrillation Patients Undergoing Catheter Ablation
Munich (ots/PRNewswire) - - ELIMINATE-AF is the first set of data presented in 2019 from the Edoxaban Clinical Research Programme, which will deliver new evidence to support the use of edoxaban in clinical practice - Late-breaking data presented at EHRA 2019, the annual congress of the European Heart Rhythm ...
plus

28.02.2019 – 13:01
Daiichi Sankyo Europe and Esperion Announce Validation of the Marketing Authorisation Application (MAA) for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet
Munich and Ann Arbor, Michigan (ots/PRNewswire) - - Application is based on results of a robust development programme, which demonstrated that bempedoic acid was well tolerated and efficacious for chronic use - Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces ...
plus
07.01.2019 – 08:01
Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet
Munich (ots/PRNewswire) - - Daiichi Sankyo Europe will market oral bempedoic acid and bempedoic acid / ezetimibe combination tablet in the European Economic Area and Switzerland - Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis ...
plus
06.08.2018 – 09:01
New Analysis Identifies Patient Populations With Cancer-associated VTE Who Could Benefit From Treatment With Oral, Once-daily LIXIANA® (edoxaban)
Munich (ots/PRNewswire) - - Hokusai-VTE CANCER study showed that oral edoxaban is non-inferior to subcutaneous injectable dalteparin, for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in cancer-associated VTE - This analysis provides benefit/risk assessment in different types of ...
plus
18.05.2018 – 14:07
LIXIANA® (edoxaban) Shows Reduced Rate of a Variety of Types of Intracranial Haemorrhage Compared to Warfarin in New Sub-analysis Presented at the European Stroke Organisation Conference 2018
Munich (ots/PRNewswire) - - Sub-analysis presented from ENGAGE AF-TIMI 48, the longest single comparative global trial of a non-vitamin K oral anticoagulant (NOAC) in patients with non-valvular atrial fibrillation (NVAF) to date - Results showed a reduction in both spontaneous and traumatic intracranial haemorrhage ...
plus
12.12.2017 – 13:53
Once-Daily, Oral LIXIANA® (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study
Munich (ots/PRNewswire) - For EU media only - not for US journalists - Hokusai-VTE CANCER study is a phase 3b, prospective, randomised, open-label, blind end-point (PROBE) study evaluating edoxaban versus low molecular weight heparin (LMWH) dalteparin in venous thromboembolism (VTE) associated with primarily active ...
plus
29.08.2017 – 14:03
New Sub-analysis Data Highlights the Benefit of LIXIANA® (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk Scoring
Munich (ots/PRNewswire) - - Sub-analysis highlights the protective effect of edoxaban against stroke or systemic embolic events (SEEs) and its superior safety in terms of major bleeding risk compared to warfarin, in non-valvular atrial fibrillation (NVAF) patients at varying levels of stroke risk.[1] - The data is ...
plus
17.07.2017 – 09:02
CHMP Issues a Positive Opinion for Daiichi Sankyo's Once-Daily LIXIANA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion
Munich (ots/PRNewswire) - - Recommended label update for LIXIANA® provides guidance on its use in patients undergoing transoesophageal echocardiography (TEE)-guided and delayed cardioversion - Update is based on data from ENSURE-AF, the largest prospective randomised clinical trial of anticoagulation for ...
plus
27.04.2017 – 15:03
Daiichi Sankyo Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily LIXIANA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation
Munich (ots/PRNewswire) - - ENVISAGE-TAVI AF is the first study to evaluate the effects of a novel oral anticoagulant on clinical outcomes exclusively in atrial fibrillation patients following successful transcatheter aortic valve implantation - Study adds to the growing Edoxaban Clinical Research Programme (ECRP) ...
plus
30.03.2017 – 14:01
Daiichi Sankyo Initiates ELIMINATE-AF Study Investigating Once-Daily LIXIANA® (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation
Munich (ots/PRNewswire) - - Study adds to the growing Edoxaban Clinical Research Programme (ECRP) evaluating its use in a broad range of cardiovascular conditions, patient types and clinical settings Daiichi Sankyo Europe GmbH (hereafter, "Daiichi Sankyo") today announced that the first patient has been enrolled ...
plus

08.12.2016 – 13:02
Daiichi Sankyo Announces Initiation of Real-World Study in LIXIANA® (edoxaban) Patients Undergoing Diagnostic and Therapeutic Procedures in NVAF and VTE
Munich (ots/PRNewswire) - First patient enrolled in EMIT-AF/VTE study (NCT02950168), a European registry to assess edoxaban management in patients undergoing medical procedures[1] Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced that the first patient has been enrolled in the EMIT-AF/VTE ...
plus
27.10.2016 – 09:37
World Stroke Day 2016: Research Reveals Delayed Diagnosis Leaves Atrial Fibrillation Patients at Major Stroke Risk
Munich (ots/PRNewswire) - - Atrial fibrillation (AF) increases the risk of a severe stroke,[1] however almost half of patients are unaware of the risk[2] - The AFfect survey revealed that one in two patients had not heard of the condition at time of diagnosis[2] - World Stroke Day is on Saturday 29th October, find ...
plus
27.10.2016 – 09:03
World Stroke Day 2016: Research Reveals Delayed Diagnosis Leaves Atrial Fibrillation Patients at Major Stroke Risk
Munich (ots/PRNewswire) - - Atrial fibrillation (AF) increases the risk of a severe stroke,[1] however almost half of patients are unaware of the risk[2] - The AFfect survey revealed that one in two patients had not heard of the condition at time of diagnosis[2] - World Stroke Day is on Saturday 29th October, find ...
plus
13.10.2016 – 09:02
Daiichi Sankyo Announces New Data to be Presented at the ISPOR EU Congress 2016 Analysing the Safety, Efficacy and Cost-effectiveness of LIXIANA® (edoxaban)
Munich (ots/PRNewswire) - - Three abstracts highlight the economic burden of Venous Thromboembolism (VTE) in Europe and provide new insights into VTE treatment with LIXIANA®(edoxaban) - Daiichi Sankyo is committed to enhancing the understanding, prevention and treatment of VTE, and is partnering with the ...
plus
30.09.2016 – 11:04
New Analysis Shows Maintained Efficacy and Safety of LIXIANA® (edoxaban) in Patients with Acute VTE Requiring a Reduced Dose Based on Clinical Criteria
Munich (ots/PRNewswire) - Results highlight the benefits of reduced dose edoxaban compared to warfarin in a potentially higher risk venous thromboembolism (VTE) patient population[1] Daiichi Sankyo Europe GmbH (hereafter Daiichi Sankyo) today announced data from a new analysis of the phase 3 Hokusai-VTE study, which ...
plus
30.08.2016 – 09:02
ENSURE-AF Data Support the Efficacy and Safety Profile of Daiichi Sankyo's Once-Daily LIXIANA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion
Munich (ots/PRNewswire) - Not for US or UK media - ENSURE-AF is the largest clinical trial of a non-vitamin K antagonist oral anticoagulant in patients with non-valvular atrial fibrillation - who undergo electrical cardioversion - ENSURE-AF is a Prospective, Randomized, Open-Label, Blinded E ndpoint evaluation ...
plus
29.08.2016 – 08:31
Real World Data From PREFER in AF Patient Registry Highlights Increased Stroke Risk Among Diabetes Patients in Atrial Fibrillation
Munich (ots/PRNewswire) - Sub-analysis data from atrial fibrillation patient registry sponsored by Daiichi Sankyo reveals at-risk patient groups and recent trends in disease management[1],[2] Not for US media Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced data from new sub-analyses of the ...
plus
24.08.2016 – 09:01
Data from Phase 3b ENSURE-AF Study Investigating Once-Daily LIXIANA® (edoxaban)in Patients with Atrial Fibrillation Undergoing Cardioversion Among 13 Daiichi Sankyo Clinical Presentations at ESC Congress 2016
Munich (ots/PRNewswire) - - ENSURE-AF results to be featured during a late-breaking clinical trial session - Five abstracts highlighting analyses from the global phase 3 ENGAGE AF-TIMI 48 study to be presented - Seven abstracts to reveal new findings from the PREFER in AF and VTE European patient registries Daiichi ...
plus
24.03.2016 – 13:01
Daiichi Sankyo to Present Findings From New Subgroup Analyses of Once-Daily LIXIANA® (edoxaban) in NVAF and VTE at ACC's 65th Annual Scientific Session
Munich (ots/PRNewswire) - - Four abstracts highlight new subgroup analyses from the global phase 3 ENGAGE AF-TIMI 48 and Hokusai-VTE studies to be presented in oral and poster sessions Daiichi Sankyo Europe GmbH Group (hereafter, Daiichi Sankyo) today announced that data from three new subgroup analyses from the ...
plus
17.02.2016 – 08:01
Daiichi Sankyo Launches Once-Daily LIXIANA? Sales Alliance in Europe
Tokyo (ots/PRNewswire) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that its European subsidiary, Daiichi Sankyo Europe GmbH Group (headquartered in Munich, Germany; hereafter, DSE), has granted exclusive rights to Merck & Co, Inc., Kenilworth, NJ, USA (NYSE: MRK), known as MSD outside the US and Canada (hereafter, MSD) to market the oral, once-daily anti-coagulant, LIXIANA® (edoxaban), ...
plus
22.01.2016 – 13:01
German Federal Joint Committee recognises added benefit of once-daily LIXIANA® (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation
Munich (ots/PRNewswire) - Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced that the German public health agency, The Federal Joint Committee (Gemeinsamer Bundesausschuss - G-BA), has granted an indication of a minor additional benefit for LIXIANA® (edoxaban), an oral, once-daily selective ...
plus
28.10.2015 – 09:01
World Stroke Day: Key Risk Factors Atrial Fibrillation and Hypertension Need Detection and Treatment
Munich (ots/PRNewswire) - - On World Stroke Day (29 October) a campaign by Daiichi Sankyo highlights stroke risks associated with cardiovascular diseases - People with atrial fibrillation have a five times higher stroke risk compared to the general population.[1] In Europe less than 50% of patients with ...
plus

123Suivant